Use of human epididymis protein 4 (HE4) to assess responsiveness of MUC16 positive cancer treatment

摘要

The present invention relates to, among other things, methods and kits or articles associated therewith that find use in assessing cancer responsiveness to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the method measures the expression level of HE4 in a sample derived from the subject and determines the expression level of HE4 in the sample from the expression previously obtained from the subject. Comparing to the level and optionally administering to the subject a therapeutically effective amount of a MUC16 antagonist. [Selection figure] None